Related Experiment Video
Updated: Jul 30, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
Advances in the Management of Cardiogenic Shock
Jacob C Jentzer1, Janine Pöss2, Hannah Schaubroeck3
1Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
Objectives:
To review a contemporary approach to the management of patients with cardiogenic shock (CS).
Data Sources:
We reviewed salient medical literature regarding CS.
Study Selection:
We included professional society scientific statements and clinical studies examining outcomes in patients with CS, with a focus on randomized clinical trials.
Data Extraction:
We extracted salient study results and scientific statement recommendations regarding the management of CS.
Data Synthesis:
Professional society recommendations were integrated with evaluated studies.
Conclusions:
CS results in short-term mortality exceeding 30% despite standard therapy. While acute myocardial infarction (AMI) has been the focus of most CS research, heart failure-related CS now predominates at many centers. CS can present with a wide spectrum of shock severity, including patients who are normotensive despite ongoing hypoperfusion. The Society for Cardiovascular Angiography and Intervention Shock Classification categorizes patients with or at risk of CS according to shock severity, which predicts mortality. The CS population includes a heterogeneous mix of phenotypes defined by ventricular function, hemodynamic profile, biomarkers, and other clinical variables. Integrating the shock severity and CS phenotype with nonmodifiable risk factors for mortality can guide clinical decision-making and prognostication. Identifying and treating the cause of CS is crucial for success, including early culprit vessel revascularization for AMI. Vasopressors and inotropes titrated to restore arterial pressure and perfusion are the cornerstone of initial medical therapy for CS. Temporary mechanical circulatory support (MCS) is indicated for appropriately selected patients as a bridge to recovery, decision, durable MCS, or heart transplant. Randomized controlled trials have not demonstrated better survival with the routine use of temporary MCS in patients with CS. Accordingly, a multidisciplinary team-based approach should be used to tailor the type of hemodynamic support to each individual CS patient's needs based on shock severity, phenotype, and exit strategy.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure V: Medical Management
Acute Coronary Syndrome IV: Interprofessional Care
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

